CN113759123A - 尿液软骨间层蛋白及其多肽片段在烧伤中的应用 - Google Patents

尿液软骨间层蛋白及其多肽片段在烧伤中的应用 Download PDF

Info

Publication number
CN113759123A
CN113759123A CN202010504023.1A CN202010504023A CN113759123A CN 113759123 A CN113759123 A CN 113759123A CN 202010504023 A CN202010504023 A CN 202010504023A CN 113759123 A CN113759123 A CN 113759123A
Authority
CN
China
Prior art keywords
burn
urine
arg
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010504023.1A
Other languages
English (en)
Inventor
张曼
王佶图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010504023.1A priority Critical patent/CN113759123A/zh
Publication of CN113759123A publication Critical patent/CN113759123A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/40Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

本发明提供一种尿液软骨间层蛋白(Cartilage intermediate‑layer protein)及其多肽片段的应用,具体为尿液软骨间层蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。烧伤是日常生活中常见的重要创伤,每年每100万人中约有5000~100000人烧伤,据世界卫生组织统计,每年全球死于烧伤患者超过30万人,严重烧伤救治存活率仍处于较低水平。本发明通过研究证实,与健康人(正常对照组)相比,尿液软骨间层蛋白及其多肽片段在烧伤患者中表达下调,并随烧伤程度加重而降低。可用于烧伤患者的辅助诊断及病情监测。本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液软骨间层蛋白及其多肽片段。

Description

尿液软骨间层蛋白及其多肽片段在烧伤中的应用
技术领域
本发明涉及尿液软骨间层蛋白及其多肽片段的新用途,具体涉及尿液软骨间层蛋白及其多肽片段在于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等的应用。
背景技术
烧伤是指由于火焰、高温气体、灼热的固体或液体、放射线、电能、强酸强碱等化学物质所引起的人体皮肤、组织甚至深层脏器的损伤,是一种全身性综合性疾病。烧伤后创面组织大量坏死、感染、休克及凝血功能障碍等反应可引起机体发生一系列的病理生理学变化。不同程度的烧伤对人体有着不同的影响,严重的烧伤可对人体内环境造成破坏,使烧伤患者出现各系统复杂性的病理生理变化,相关的检测指标也会随着烧伤严重程度的不同随之出现相应的改变。及时检测这些指标的变化可为临床医生对于疾病的诊断,病情的判断,治疗方法的选择以及患者预后的评估等多方面提供有价值的参考依据。
但是,严重烧伤的病人皮肤完整性较差,血液学检测作为皮肤有创性检查在此类患者的临床应用中存在着诸多困难,反复的抽血检测还会加剧患者痛苦。尿液作为血液的超滤液蕴含着丰富的生物学信息,其采集过程具有无创便捷等优势,这在烧伤患者的检测中尤为明显。在尿液中寻找有助于烧伤诊断及反映病情变化的生物标志物,可提高烧伤患者的生活质量和依从性,减轻多次采血的痛苦,更好的为临床医生提供有利于疾病诊断和治疗的参考依据。
软骨间层蛋白(cartilage Intermediate layer Protein,CILP)是人类关节软骨的基质组成成分.因其分布只局限于软骨组织特别是在软骨中间层分布丰富而得名。但目前在半月板、肌腱、韧带、滑膜及椎间盘均发现其存在,目前可对该蛋白的研究较少。本研究烧伤患者尿液中软骨间层蛋白较健康人组出现表达下调,且与烧伤程度呈一定相关性,烧伤程度越严重该蛋白含量越低。
与常用的临床血液样本相比,尿液可以完全无创、连续、大量收集;没有稳态调节,可累积更多种类、更大幅度的变化,机体的很多病理生理变化可能体现在尿液中。一些激素和细胞因子等分子量相对较小的蛋白多肽入血后,会很快被排泄进入尿液,这些蛋白和多肽在尿液中被检测到的概率比在血中大很多;尿液收集之前,尿中可能的蛋白降解过程已经完成,所以尿蛋白可在较长时间内保持稳定。为减轻烧伤患者多次采血的痛苦,本实验在前期方法学摸索的基础上,期望通过尿液蛋白或多肽研究,实现用无痛、方便、快捷、易重复的尿液检测辅助烧伤患者的诊断及病情监测,也为进一步尿液多肽检测试剂盒的研究奠定基础。
发明内容
本发明的目的在于提供一种尿液软骨间层蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。
优选地,所述尿液软骨间层蛋白的氨基酸序列如SEQ ID NO.1所示(MVGTKAWVFSFLVLEVTSVL GRQTMLTQSV RRVQPGKKNP SIFAKPADTL ESPGEWTTWF NIDYPGGKGD YERLDAIRFYYGDRVCARPL RLEARTTDWT PAGSTGQVVH GSPREGFWCL NREQRPGQNC SNYTVRFLCP PGSLRRDTERIWSPWSPWSK CSAACGQTGV QTRTRICLAE MVSLCSEASE EGQHCMGQDC TACDLTCPMG QVNADCDACMCQDFMLHGAV SLPGGAPASG AAIYLLTKTP KLLTQTDSDG RFRIPGLCPD GKSILKITKV KFAPIVLTMPKTSLKAATIK AEFVRAETPY MVMNPETKAR RAGQSVSLCC KATGKPRPDK YFWYHNDTLL DPSLYKHESKLVLRKLQQHQ AGEYFCKAQS DAGAVKSKVA QLIVIASDET PCNPVPESYL IRLPHDCFQN ATNSFYYDVGRCPVKTCAGQ QDNGIRCRDA VQNCCGISKT EEREIQCSGY TLPTKVAKEC SCQRCTETRS IVRGRVSAADNGEPMRFGHV YMGNSRVSMT GYKGTFTLHV PQDTERLVLT FVDRLQKFVN TTKVLPFNKK GSAVFHEIKMLRRKKPITLE AMETNIIPLG EVVGEDPMAE LEIPSRSFYR QNGEPYIGKV KASVTFLDPR NISTATAAQTDLNFINDEGD TFPLRTYGMF SVDFRDEVTS EPLNAGKVKV HLDSTQVKMP EHISTVKLWS LNPDTGLWEEEGDFKFENQR RNKREDRTFL VGNLEIRERR LFNLDVPESR RCFVKVRAYR SERFLPSEQI QGVVISVINLEPRTGFLSNP RAWGRFDSVI TGPNGACVPA FCDDQSPDAY SAYVLASLAG EELQAVESSP KFNPNAIGVPQPYLNKLNYR RTDHEDPRVK KTAFQISMAK PRPNSAEESN GPIYAFENLR ACEEAPPSAA HFRFYQIEGDRYDYNTVPFN EDDPMSWTED YLAWWPKPME FRACYIKVKI VGPLEVNVRS RNMGGTHRQT VGKLYGIRDVRSTRDRDQPN VSAACLEFKC SGMLYDQDRV DRTLVKVIPQ GSCRRASVNP MLHEYLVNHL PLAVNNDTSEYTMLAPLDPL GHNYGIYTVT DQDPRTAKEI ALGRCFDGTS DGSSRIMKSN VGVALTFNCV ERQVGRQSAFQYLQSTPAQS PAAGTVQGRV PSRRQQRASR GGQRQGGVVA SLRFPRVAQQ PLIN);或由SEQ ID NO.1所示的氨基酸序列衍生的,且与SEQ ID NO.1所示的氨基酸序列具有相同功能的氨基酸序列。
优选地,所述制剂为烧伤患者尿液软骨间层蛋白及其多肽片段检测试剂盒。
优选地,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合软骨间层蛋白及其多肽片段的适配体抗体或抗体片段中的一种或多种。
优选地,所述检测方法包括直接检测软骨间层蛋白及其多肽片段的质谱等方法及其相关试剂盒。
优选地,所述检测方法包括直接检测软骨间层蛋白其多肽片段的相关核酸检测等方法及其相关试剂盒。
优选地,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
优选地,所述标准品包括软骨间层蛋白标准品、人源化标签抗体标准品;较佳地,所述质控品包括:软骨间层蛋白质控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
优选地,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
发明人首先收集了健康人、不同烧伤程度患者的尿液标本, 4000r/min离心5min后,吸取上清,采用Bradford法测定提取的蛋白浓度,进行SDS-PAGE酶解。尿液样本的Label-free质谱分析由OrbitrapFusion型质谱完成。将烧伤组和正常对照组在质谱中得到的数据采用Maxquant算法中的Labelfree算法进行非标记定量计算。以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异性多肽。然后发明人对具有统计学意义的差异性多肽进行鉴定,利用数据库检索得到差异蛋白软骨间层蛋白。
本发明通过研究证实与健康人相比,软骨间层蛋白及其多肽片段在烧伤患者的尿液中呈低表达,并随烧伤程度的加重而降低,与临床诊断有较好的一致性。从而提出检测尿液软骨间层蛋白及其多肽片段可用于烧伤的辅助诊断或病情监测。
本发明发挥尿液标本获取无创、可大规模重复取样、保存方便的优势,利用尿液标本检测尿液软骨间层蛋白及其多肽片段。
为让本发明的上述和其它目的、特征和优点能更明显易懂,下文特举较佳实施例,并配合附图,作详细说明如下。
附图说明
图1是尿液软骨间层蛋白及其多肽片段在烧伤组及健康对照组中含量图。
图2是软骨间层蛋白参与主要生物过程示意图。
具体实施方式
实施例1 尿液标本的收集与处理
选取烧伤患者作为烧伤组,选取同期健康体检者作为正常对照组。收集各组研究对象入院后的新鲜晨尿样本30ml,不能正常排尿者收集其早晨导尿管中尿液,置于干燥、洁净的容器内。将收集的尿液标本4000r/min离心5min后,吸取上清,每管2ml分装,-80℃冰箱保存。
实施例2 质谱分析和尿液多肽的筛选
对尿液样品蛋白提取,并对提取的蛋白浓度进行测定。尿液样本的质谱分析由OrbitrapFusion型质谱完成。将实验组和正常对照组在质谱中得到的数据进行定量计算。组间比较采用t-test进行差异分析,以蛋白表达量差异在1.5倍以上且经统计检验P<0.05作为参考标准筛选差异表达蛋白。
实施例3 差异多肽的鉴定及分析
本次使用的数据库为Uniprot_Homo数据库,产生的质谱原始文件采用MaxQuant软件处理,检索参数设置见表1。
Figure DEST_PATH_IMAGE001
与健康人相比,软骨间层蛋白在烧伤患者的尿液中低表达,如图1所示,其参与的主要生物过程如图2所示,软骨间层蛋白在正常对照组和烧伤组尿液中的表达有显著性差异,并随烧伤程度的加重而降低。
虽然本发明已以较佳实施例披露如上,然其并非用以限定本发明,任何所属技术领域的技术人员,在不脱离本发明的精神和范围内,当可作些许的更动与改进,因此本发明的保护范围当视权利要求所界定者为准。
序列表
<110>张曼
<120> 尿液软骨间层蛋白及其多肽片段在烧伤中的应用
<130> 1
<140> 20PCILP-CN
<141> 2020-05-03
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1184
<212> PRT
<213> Human Urine
<400> 1
Met Val Gly Thr Lys Ala Trp Val Phe Ser Phe Leu Val Leu Glu Val
1 5 10 15
Thr Ser Val Leu Gly Arg Gln Thr Met Leu Thr Gln Ser Val Arg Arg
20 25 30
Val Gln Pro Gly Lys Lys Asn Pro Ser Ile Phe Ala Lys Pro Ala Asp
35 40 45
Thr Leu Glu Ser Pro Gly Glu Trp Thr Thr Trp Phe Asn Ile Asp Tyr
50 55 60
Pro Gly Gly Lys Gly Asp Tyr Glu Arg Leu Asp Ala Ile Arg Phe Tyr
65 70 75 80
Tyr Gly Asp Arg Val Cys Ala Arg Pro Leu Arg Leu Glu Ala Arg Thr
85 90 95
Thr Asp Trp Thr Pro Ala Gly Ser Thr Gly Gln Val Val His Gly Ser
100 105 110
Pro Arg Glu Gly Phe Trp Cys Leu Asn Arg Glu Gln Arg Pro Gly Gln
115 120 125
Asn Cys Ser Asn Tyr Thr Val Arg Phe Leu Cys Pro Pro Gly Ser Leu
130 135 140
Arg Arg Asp Thr Glu Arg Ile Trp Ser Pro Trp Ser Pro Trp Ser Lys
145 150 155 160
Cys Ser Ala Ala Cys Gly Gln Thr Gly Val Gln Thr Arg Thr Arg Ile
165 170 175
Cys Leu Ala Glu Met Val Ser Leu Cys Ser Glu Ala Ser Glu Glu Gly
180 185 190
Gln His Cys Met Gly Gln Asp Cys Thr Ala Cys Asp Leu Thr Cys Pro
195 200 205
Met Gly Gln Val Asn Ala Asp Cys Asp Ala Cys Met Cys Gln Asp Phe
210 215 220
Met Leu His Gly Ala Val Ser Leu Pro Gly Gly Ala Pro Ala Ser Gly
225 230 235 240
Ala Ala Ile Tyr Leu Leu Thr Lys Thr Pro Lys Leu Leu Thr Gln Thr
245 250 255
Asp Ser Asp Gly Arg Phe Arg Ile Pro Gly Leu Cys Pro Asp Gly Lys
260 265 270
Ser Ile Leu Lys Ile Thr Lys Val Lys Phe Ala Pro Ile Val Leu Thr
275 280 285
Met Pro Lys Thr Ser Leu Lys Ala Ala Thr Ile Lys Ala Glu Phe Val
290 295 300
Arg Ala Glu Thr Pro Tyr Met Val Met Asn Pro Glu Thr Lys Ala Arg
305 310 315 320
Arg Ala Gly Gln Ser Val Ser Leu Cys Cys Lys Ala Thr Gly Lys Pro
325 330 335
Arg Pro Asp Lys Tyr Phe Trp Tyr His Asn Asp Thr Leu Leu Asp Pro
340 345 350
Ser Leu Tyr Lys His Glu Ser Lys Leu Val Leu Arg Lys Leu Gln Gln
355 360 365
His Gln Ala Gly Glu Tyr Phe Cys Lys Ala Gln Ser Asp Ala Gly Ala
370 375 380
Val Lys Ser Lys Val Ala Gln Leu Ile Val Ile Ala Ser Asp Glu Thr
385 390 395 400
Pro Cys Asn Pro Val Pro Glu Ser Tyr Leu Ile Arg Leu Pro His Asp
405 410 415
Cys Phe Gln Asn Ala Thr Asn Ser Phe Tyr Tyr Asp Val Gly Arg Cys
420 425 430
Pro Val Lys Thr Cys Ala Gly Gln Gln Asp Asn Gly Ile Arg Cys Arg
435 440 445
Asp Ala Val Gln Asn Cys Cys Gly Ile Ser Lys Thr Glu Glu Arg Glu
450 455 460
Ile Gln Cys Ser Gly Tyr Thr Leu Pro Thr Lys Val Ala Lys Glu Cys
465 470 475 480
Ser Cys Gln Arg Cys Thr Glu Thr Arg Ser Ile Val Arg Gly Arg Val
485 490 495
Ser Ala Ala Asp Asn Gly Glu Pro Met Arg Phe Gly His Val Tyr Met
500 505 510
Gly Asn Ser Arg Val Ser Met Thr Gly Tyr Lys Gly Thr Phe Thr Leu
515 520 525
His Val Pro Gln Asp Thr Glu Arg Leu Val Leu Thr Phe Val Asp Arg
530 535 540
Leu Gln Lys Phe Val Asn Thr Thr Lys Val Leu Pro Phe Asn Lys Lys
545 550 555 560
Gly Ser Ala Val Phe His Glu Ile Lys Met Leu Arg Arg Lys Lys Pro
565 570 575
Ile Thr Leu Glu Ala Met Glu Thr Asn Ile Ile Pro Leu Gly Glu Val
580 585 590
Val Gly Glu Asp Pro Met Ala Glu Leu Glu Ile Pro Ser Arg Ser Phe
595 600 605
Tyr Arg Gln Asn Gly Glu Pro Tyr Ile Gly Lys Val Lys Ala Ser Val
610 615 620
Thr Phe Leu Asp Pro Arg Asn Ile Ser Thr Ala Thr Ala Ala Gln Thr
625 630 635 640
Asp Leu Asn Phe Ile Asn Asp Glu Gly Asp Thr Phe Pro Leu Arg Thr
645 650 655
Tyr Gly Met Phe Ser Val Asp Phe Arg Asp Glu Val Thr Ser Glu Pro
660 665 670
Leu Asn Ala Gly Lys Val Lys Val His Leu Asp Ser Thr Gln Val Lys
675 680 685
Met Pro Glu His Ile Ser Thr Val Lys Leu Trp Ser Leu Asn Pro Asp
690 695 700
Thr Gly Leu Trp Glu Glu Glu Gly Asp Phe Lys Phe Glu Asn Gln Arg
705 710 715 720
Arg Asn Lys Arg Glu Asp Arg Thr Phe Leu Val Gly Asn Leu Glu Ile
725 730 735
Arg Glu Arg Arg Leu Phe Asn Leu Asp Val Pro Glu Ser Arg Arg Cys
740 745 750
Phe Val Lys Val Arg Ala Tyr Arg Ser Glu Arg Phe Leu Pro Ser Glu
755 760 765
Gln Ile Gln Gly Val Val Ile Ser Val Ile Asn Leu Glu Pro Arg Thr
770 775 780
Gly Phe Leu Ser Asn Pro Arg Ala Trp Gly Arg Phe Asp Ser Val Ile
785 790 795 800
Thr Gly Pro Asn Gly Ala Cys Val Pro Ala Phe Cys Asp Asp Gln Ser
805 810 815
Pro Asp Ala Tyr Ser Ala Tyr Val Leu Ala Ser Leu Ala Gly Glu Glu
820 825 830
Leu Gln Ala Val Glu Ser Ser Pro Lys Phe Asn Pro Asn Ala Ile Gly
835 840 845
Val Pro Gln Pro Tyr Leu Asn Lys Leu Asn Tyr Arg Arg Thr Asp His
850 855 860
Glu Asp Pro Arg Val Lys Lys Thr Ala Phe Gln Ile Ser Met Ala Lys
865 870 875 880
Pro Arg Pro Asn Ser Ala Glu Glu Ser Asn Gly Pro Ile Tyr Ala Phe
885 890 895
Glu Asn Leu Arg Ala Cys Glu Glu Ala Pro Pro Ser Ala Ala His Phe
900 905 910
Arg Phe Tyr Gln Ile Glu Gly Asp Arg Tyr Asp Tyr Asn Thr Val Pro
915 920 925
Phe Asn Glu Asp Asp Pro Met Ser Trp Thr Glu Asp Tyr Leu Ala Trp
930 935 940
Trp Pro Lys Pro Met Glu Phe Arg Ala Cys Tyr Ile Lys Val Lys Ile
945 950 955 960
Val Gly Pro Leu Glu Val Asn Val Arg Ser Arg Asn Met Gly Gly Thr
965 970 975
His Arg Gln Thr Val Gly Lys Leu Tyr Gly Ile Arg Asp Val Arg Ser
980 985 990
Thr Arg Asp Arg Asp Gln Pro Asn Val Ser Ala Ala Cys Leu Glu Phe
995 1000 1005
Lys Cys Ser Gly Met Leu Tyr Asp Gln Asp Arg Val Asp Arg Thr Leu
1010 1015 1020
Val Lys Val Ile Pro Gln Gly Ser Cys Arg Arg Ala Ser Val Asn Pro
1025 1030 1035 1040
Met Leu His Glu Tyr Leu Val Asn His Leu Pro Leu Ala Val Asn Asn
1045 1050 1055
Asp Thr Ser Glu Tyr Thr Met Leu Ala Pro Leu Asp Pro Leu Gly His
1060 1065 1070
Asn Tyr Gly Ile Tyr Thr Val Thr Asp Gln Asp Pro Arg Thr Ala Lys
1075 1080 1085
Glu Ile Ala Leu Gly Arg Cys Phe Asp Gly Thr Ser Asp Gly Ser Ser
1090 1095 1100
Arg Ile Met Lys Ser Asn Val Gly Val Ala Leu Thr Phe Asn Cys Val
1105 1110 1115 1120
Glu Arg Gln Val Gly Arg Gln Ser Ala Phe Gln Tyr Leu Gln Ser Thr
1125 1130 1135
Pro Ala Gln Ser Pro Ala Ala Gly Thr Val Gln Gly Arg Val Pro Ser
1140 1145 1150
Arg Arg Gln Gln Arg Ala Ser Arg Gly Gly Gln Arg Gln Gly Gly Val
1155 1160 1165
Val Ala Ser Leu Arg Phe Pro Arg Val Ala Gln Gln Pro Leu Ile Asn
1170 1175 1180

Claims (9)

1.尿液软骨间层蛋白及其多肽片段在制备用于烧伤诊断、鉴别诊断、烧伤面积及程度评价、治疗效果评价、监测、预后评估及机理研究等制剂的应用。
2.根据权利要求1所述的应用,其特征在于,所述尿液软骨间层蛋白的氨基酸序列如SEQ ID NO.1所示;或由SEQ ID NO.1所示的氨基酸序列衍生的,且与SEQ ID NO.1所示的氨基酸序列具有相同功能的氨基酸序列。
3.根据权利要求1所述的应用,其特征在于,所述制剂为烧伤患者尿液软骨间层蛋白及其多肽片段检测试剂盒。
4.根据权利要求3所述的应用,其特征在于,所述试剂盒包括抗原抗体反应的免疫方法及其试剂盒如能够特异性结合软骨间层蛋白及其多肽片段的适配体抗体或抗体片段中的一种或多种。
5.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测软骨间层蛋白及其多肽片段的质谱等方法及其相关试剂盒。
6.根据权利要求3所述的应用,其特征在于,所述检测方法包括直接检测软骨间层蛋白及其多肽片段的相关核酸检测等方法及其相关试剂盒。
7.根据权利要求3所述的应用,其特征在于,所述试剂盒还包括选自下组的成分:固相载体,稀释液,对照品,标准品,质控品,检测抗体,第二抗体、第二抗体稀释液,发光试剂,洗涤液、显色液、终止液中的任意一种或几种的组合。
8.根据权利要求7所述的应用,其特征在于,所述标准品包括软骨间层蛋白标准品、人源化标签抗体标准品;较佳地,所述质控品包括:软骨间层蛋白控品、人源化标签抗体质控品;较佳地,所述固相载体包括:微粒、微球、玻片、试纸条、塑料珠、液相芯片、微孔板或亲和膜等以及同等功能的其他载体。
9.根据权利要求8所述的应用,其特征在于,所述固相载体的材质为聚氯乙烯、聚苯乙烯、聚丙酰胺、纤维素中的任意一种及具有类似功能的载体。
CN202010504023.1A 2020-06-05 2020-06-05 尿液软骨间层蛋白及其多肽片段在烧伤中的应用 Pending CN113759123A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010504023.1A CN113759123A (zh) 2020-06-05 2020-06-05 尿液软骨间层蛋白及其多肽片段在烧伤中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010504023.1A CN113759123A (zh) 2020-06-05 2020-06-05 尿液软骨间层蛋白及其多肽片段在烧伤中的应用

Publications (1)

Publication Number Publication Date
CN113759123A true CN113759123A (zh) 2021-12-07

Family

ID=78783957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010504023.1A Pending CN113759123A (zh) 2020-06-05 2020-06-05 尿液软骨间层蛋白及其多肽片段在烧伤中的应用

Country Status (1)

Country Link
CN (1) CN113759123A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045197A2 (de) * 2005-10-21 2007-04-26 Justus Liebig Universität Giessen Erfindung betreffend expressionsprofile zur vorhersage von septischen zuständen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045197A2 (de) * 2005-10-21 2007-04-26 Justus Liebig Universität Giessen Erfindung betreffend expressionsprofile zur vorhersage von septischen zuständen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵乔妹;刘丹;雷婷;张曼;: "不同程度烧伤患者凝血功能变化及意义", 标记免疫分析与临床, no. 05, 25 May 2019 (2019-05-25), pages 36 - 40 *

Similar Documents

Publication Publication Date Title
CN113777314A (zh) 尿液踝蛋白1及其多肽片段在烧伤中的应用
CN113759123A (zh) 尿液软骨间层蛋白及其多肽片段在烧伤中的应用
CN113777305A (zh) 尿液单腺苷二磷酸核糖基化转移酶及其多肽片段在烧伤中的应用
CN114113580A (zh) 尿液血栓调节蛋白及其多肽片段在烧伤中的应用
CN113777313A (zh) 尿液维生素k依赖性蛋白s及其多肽片段在烧伤中的应用
CN113777316A (zh) 尿液C4b结合蛋白α链及其多肽片段在烧伤中的应用
CN113777302A (zh) 尿液补体因子d及其多肽片段在烧伤中的应用
CN114113621A (zh) 尿液鸟嘌呤核苷酸结合蛋白亚基α-13及其多肽片段在烧伤中的应用
CN113759125A (zh) 尿液子宫珠蛋白及其多肽片段在烧伤中的应用
CN113777331A (zh) 尿液激肽原-1及其多肽片段在烧伤中的应用
CN113777315A (zh) 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用
CN113820485A (zh) 尿液碳酸酐酶3及其多肽片段在烧伤中的应用
CN113804890A (zh) 尿液程序性细胞死亡6相互作用蛋白及其多肽片段在烧伤中的应用
CN113804891A (zh) 尿液c反应蛋白及其多肽片段在烧伤中的应用
CN113804893A (zh) 尿液I型胶原蛋白α1链及其多肽片段在烧伤中的应用
CN113759121A (zh) 尿液免疫球蛋白κ可变区3D-7及其多肽片段在烧伤中的应用
CN113777304A (zh) 尿液纤维蛋白溶解酶原及其多肽片段在烧伤中的应用
CN113804889A (zh) 尿液XII型胶原蛋白α1链及其多肽片段在烧伤中的应用
CN114113622A (zh) 尿液鸟嘌呤核苷酸结合蛋白G(s)亚单位α短亚型及其多肽片段在烧伤中的应用
CN113777303A (zh) 尿液凝血酶原及其多肽片段在烧伤中的应用
CN113804895A (zh) 尿液免疫球蛋白重链可变区3-7及其多肽片段在烧伤中的应用
CN114113640A (zh) 尿液凝血因子ix及其多肽片段在烧伤中的应用
CN113777317A (zh) 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
CN113759122A (zh) 尿液蛋白质z及其多肽片段在烧伤中的应用
CN114113600A (zh) 尿液α1-抗胰蛋白酶及其多肽片段在烧伤中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination